Immix Biopharma, Inc. — Investor Relations & Filings
Filings indexed
212
across all filing types
Latest filing
2026-04-06
Proxy Solicitation & In…
Country
US
United States of America
Listing
US
IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for serious diseases. The company's primary strategy is to advance Chimeric Antigen Receptor T-cell (CAR-T) therapies by addressing their key limitation: neurotoxicity. By working to overcome this side effect, ImmixBio aims to expand the use of CAR-T treatments to a wider range of patients, medical centers, and new indications, with a lead program targeting AL Amyloidosis. The company is also developing a novel class of Tissue-Specific Therapeutics (TSTx) for applications in oncology and inflammation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEF 14A - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-04-06 | English | |
| 8-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-30 | English | |
| 10-K/A - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-27 | English | |
| S-8 - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | |
| 8-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | |
| 424B5 - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 33642490 | DEF 14A - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-04-06 | English | ||
| 33092916 | 8-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-30 | English | ||
| 33066426 | 10-K/A - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-27 | English | ||
| 33043171 | S-8 - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33043144 | 8-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33043132 | 424B5 - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33043109 | 10-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33002269 | SCHEDULE 13G - Immix Biopharma, Inc. (0001873835) (Subject) | 2026-03-20 | English | ||
| 32145665 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 32145663 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 13498584 | Regulatory Filings 2026 | 2026-01-23 | English | ||
| 13498585 | S-3 | 2026-01-09 | English | ||
|
2025
3 filings
| |||||
| 13498586 | 4 | 2025-12-12 | English | ||
| 13498587 | 4 | 2025-12-11 | English | ||
| 13498588 | 4 | 2025-12-11 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Immix Biopharma, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34423/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34423 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34423 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34423 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34423}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Immix Biopharma, Inc. (id: 34423)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.